These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

783 related articles for article (PubMed ID: 25738213)

  • 1. The impact of diabetes and diabetes medications on bone health.
    Gilbert MP; Pratley RE
    Endocr Rev; 2015 Apr; 36(2):194-213. PubMed ID: 25738213
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacologic management of the older patient with type 2 diabetes mellitus.
    Neumiller JJ; Setter SM
    Am J Geriatr Pharmacother; 2009 Dec; 7(6):324-42. PubMed ID: 20129254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complementing insulin therapy to achieve glycemic control.
    Barnett AH
    Adv Ther; 2013 Jun; 30(6):557-76. PubMed ID: 23797471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluating second-line treatment options for type 2 diabetes: focus on secondary effects of GLP-1 agonists and DPP-4 inhibitors.
    Boland CL; Degeeter M; Nuzum DS; Tzefos M
    Ann Pharmacother; 2013 Apr; 47(4):490-505. PubMed ID: 23548652
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incretin enhancers and the evolution of antihyperglycemic therapy in type 2 diabetes.
    Inzucchi SE
    Endocrinol Metab Clin North Am; 2007 Dec; 36 Suppl 2 Incretin():2-17. PubMed ID: 18405144
    [No Abstract]   [Full Text] [Related]  

  • 6. Cardiovascular benefits and safety of non-insulin medications used in the treatment of type 2 diabetes mellitus.
    Yandrapalli S; Jolly G; Horblitt A; Sanaani A; Aronow WS
    Postgrad Med; 2017 Nov; 129(8):811-821. PubMed ID: 28749197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes.
    Ferrannini E; DeFronzo RA
    Eur Heart J; 2015 Sep; 36(34):2288-96. PubMed ID: 26063450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Drugs Used in Pharmacotherapy of Type 2 Diabetes on Bone Density and Risk of Bone Fractures.
    Wikarek A; Grabarczyk M; Klimek K; Janoska-Gawrońska A; Suchodolska M; Holecki M
    Medicina (Kaunas); 2024 Feb; 60(3):. PubMed ID: 38541119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. What to add in with metformin in type 2 diabetes?
    Petrie JR; Adler A; Vella S
    QJM; 2011 Mar; 104(3):185-92. PubMed ID: 21156663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of diabetes drugs on the skeleton.
    Meier C; Schwartz AV; Egger A; Lecka-Czernik B
    Bone; 2016 Jan; 82():93-100. PubMed ID: 25913633
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of Incretin-Based Therapies and SGLT2 Inhibitors on Skeletal Health.
    Egger A; Kraenzlin ME; Meier C
    Curr Osteoporos Rep; 2016 Dec; 14(6):345-350. PubMed ID: 27709509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological management of type 2 diabetes mellitus: an update.
    El-Kaissi S; Sherbeeni S
    Curr Diabetes Rev; 2011 Nov; 7(6):392-405. PubMed ID: 21846326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of Pediatric Type 2 Diabetes.
    Smith JD; Mills E; Carlisle SE
    Ann Pharmacother; 2016 Sep; 50(9):768-77. PubMed ID: 27307414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-insulin drugs to treat hyperglycaemia in type 1 diabetes mellitus.
    Frandsen CS; Dejgaard TF; Madsbad S
    Lancet Diabetes Endocrinol; 2016 Sep; 4(9):766-780. PubMed ID: 26969516
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of dipeptidyl peptidase-4 inhibitors on bone fracture among patients with type 2 diabetes mellitus: A network meta-analysis of randomized controlled trials.
    Yang J; Huang C; Wu S; Xu Y; Cai T; Chai S; Yang Z; Sun F; Zhan S
    PLoS One; 2017; 12(12):e0187537. PubMed ID: 29206832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Second line therapy: type 2 diabetic subjects failing on metformin GLP-1/DPP-IV inhibitors versus sulphonylurea/insulin: for GLP-1/DPP-IV inhibitors.
    Kumar A
    Diabetes Metab Res Rev; 2012 Dec; 28 Suppl 2():21-5. PubMed ID: 23280862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-insulin pharmacological therapies for treating type 1 diabetes.
    Frandsen CS; Dejgaard TF; Madsbad S; Holst JJ
    Expert Opin Pharmacother; 2018 Jun; 19(9):947-960. PubMed ID: 29991320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overview of Data Concerning the Safe Use of Antihyperglycemic Medications in Type 2 Diabetes Mellitus and Chronic Kidney Disease.
    Roussel R; Lorraine J; Rodriguez A; Salaun-Martin C
    Adv Ther; 2015 Nov; 32(11):1029-64. PubMed ID: 26581749
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recommendations on the effect of antidiabetic drugs in bone.
    Rozas-Moreno P; Reyes-García R; Jódar-Gimeno E; Varsavsky M; Luque-Fernández I; Cortés-Berdonces M; Muñoz-Torres M;
    Endocrinol Diabetes Nutr; 2017 Mar; 64 Suppl 1():1-6. PubMed ID: 28440761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.
    Jellinger PS
    Postgrad Med; 2011 Jan; 123(1):53-65. PubMed ID: 21293084
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.